Developer docs
API playgroundTry for free, no card

Search company profiles

August Bioservices

Full company profile

uuid0000y4m

Namestring
August Bioservices
Legal namestring
August Bioservices, LLC
Websiteurl
augustbio.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

August Bioservices, LLC is a U.S.-based contract development and manufacturing organization (CDMO) headquartered in Nashville, Tennessee, specializing exclusively in sterile injectable drug products. Founded in 2020 through the rebranding of PMI BioPharma and led by CEO Jenn Adams, the company operates an integrated three-service model spanning product development (formulation, process development, technology transfer, and scale-up), analytical services (full USP <1> release testing, stability, elemental impurities, extractables and leachables, nitrosamines, container closure integrity), and cGMP manufacturing (1L–4000L formulation scale across seven filling lines for vials, syringes, and IV bags, plus large-scale lyophilization and automated end-of-line inspection, packaging, and serialization). The facility is compliant with FDA Sterile Injectable Guidance, EU GMP Annex 1, and an ICH-based Quality Management System, enabling service to both U.S. and European pharmaceutical and biotech sponsors.

The business model is professional-services-based: revenue is generated through negotiated, project-based CDMO contracts with pharmaceutical and biotech clients, spanning modalities that include small molecules, peptides, enzymes, biologics, controlled substances, and lipid nanoparticles. Go-to-market is enterprise field sales with dedicated CDMO Business Development leadership, supported by attendance at major industry events (DCAT, CPHI, BIO, Contract Pharma, CDMO Live) and thought-leadership content in trade publications. The company has cumulatively raised approximately $88.6 million of institutional capital — including a $23.6 million Series A extension led by Polaris Partners (May 2021) and a $65 million Series B led by Oak HC/FT (December 2022) — alongside state grants, to fund a $64.7 million campus expansion that includes a 60,000 sq ft state-of-the-art commercial manufacturing facility, 180 planned new jobs over five years, and a 2025 strategic partnership with Optima for advanced fill-finish systems.

Short descriptiontext

August Bioservices is a U.S.-based, Nashville-headquartered CDMO providing fully integrated development, analytical, and cGMP manufacturing services exclusively for sterile injectable drug products, serving pharmaceutical and biotech sponsors from clinical through commercial scale.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNashville, United States
HQ citystring
Nashville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile injectable CDMO, pharmaceutical contract manufacturing, aseptic fill-finish services, biologics manufacturing services, analytical testing services
Industry3 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Services-Testing Laboratories8734
  • Services-Commercial Physical & Biological Research8731
Product category
Sterile Injectable CDMO Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

August Bioservices generates revenue through contract development and manufacturing organization (CDMO) services for pharmaceutical and biotech companies. Services span the full product lifecycle from early formulation development through commercial-scale manufacturing of sterile injectable drug products. Revenue is project-based with long-term contract relationships typical in the CDMO industry.

augustbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Infrastructure, Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

August Bioservices is a U.S.-based Contract Development and Manufacturing Organization (CDMO) providing fully integrated drug development, analytical testing, and cGMP manufacturing services focused exclusively on sterile injectable drug products. The company serves pharmaceutical and biotechnology clients across formulation development, process development and technology transfer, comprehensive analytical and microbiological testing, and sterile fill-finish manufacturing for vials, syringes, and IV bags at scales from 1L to 4000L.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

August Bioservices is a US-based Contract Development and Manufacturing Organization (CDMO) providing fully integrated drug development, testing, and manufacturing services focused on sterile injectables. The company operates three interconnected service lines: Product Development Services (formulation, process development, technology transfer), Analytical Services (chemistry, microbiology, and characterization testing), and Manufacturing Services (sterile filling, inspection, packaging). Together these services span from early-stage lab-scale development through commercial-scale manufacturing for pharmaceutical and biotech clients.

Product and service3 records
1Product Development Services
CategoryProduct Development / CDMO
Description

Scientific product development services for sterile injectables, including formulation development (liquid, homogenization, microfluidization, rotary evaporation, lab-scale lyophilization), process development and optimization, DoE and QbD study design and statistical analysis, and technology transfer and scale-up. Serves pharmaceutical and biotech clients developing modalities such as small molecules, peptides, enzymes, biologics, controlled substances, and lipid nanoparticles.

2Analytical Services
CategoryAnalytical Services / CDMO
Description

On-site Chemistry, Microbiology, Raw Material, and Analytical Development laboratories performing full USP <1> release testing for injectables, stability testing across all ICH Zones, elemental impurity testing (ICPMS), residual solvent testing (GCMS), extractables and leachables, nitrosamines, photostability, thermal cycling, and container closure integrity testing. Supports CMC submission readiness for pharmaceutical and biotech clients.

3Manufacturing Services
CategoryManufacturing Services / CDMO
Description

cGMP sterile injectable manufacturing services covering formulation at 1L to 4000L scale using stainless steel and single-use technology, sterile filling for vials, syringes, and IV bags (including drug-device combination products), lyophilization, and automated visual inspection, assembly, labeling, packaging, and serialization. Serves pharmaceutical and biotech clients from clinical through commercial supply.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-01-01
Description

August Bio partners with Optima to enhance fill-finish flexibility with advanced systems for vials, pre-filled syringes, and cartridges. The partnership provides state-of-the-art equipment including Optima isolated high-speed vial filler and syringe filler systems. Optima's Turnkey approach and flexibility of solutions created real added value for August Bio's manufacturing operations.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Catalent is one of the largest global CDMOs with deep sterile injectable fill-finish capabilities across vials, syringes, and prefilled devices. It competes head-to-head with August Bio for clinical and commercial sterile injectable programs but operates a much broader global network and larger customer book.

TypeBroad incumbent
Description

Lonza is a global CDMO leader spanning small molecules, biologics, and cell/gene therapy, including sterile injectable drug product manufacturing. It is a relevant incumbent peer given August Bio's stated biologics and complex formulation capabilities.

TypeDirect peer
Description

Grand River is a U.S.-based CDMO focused on sterile injectable fill-finish for vials, syringes, and lyophilized products. Closely comparable to August Bio in scale, scope, and customer base of small-to-mid pharma and biotech sponsors.

TypeBroad incumbent
Description

Thermo Fisher's Pharma Services segment (including Patheon) offers large-scale sterile injectable development and manufacturing alongside oral solid dose and API services. A broader incumbent that competes with August Bio for commercial-scale sterile programs.

5Recipharm
TypeBroad incumbent
Description

Recipharm is a European-headquartered CDMO with sterile injectable manufacturing capabilities alongside other dosage forms. A relevant incumbent competitor for cross-regional pharma sponsors.

TypeBroad incumbent
Description

Piramal operates a global sterile injectable CDMO network (including its Lexington facility acquired from Coldstream). Comparable in modality coverage and customer segment to August Bio, though at larger scale.

TypeDirect peer
Description

Alcami is a U.S.-based CDMO offering sterile injectable development, manufacturing, and analytical services. Directly comparable to August Bio in services offered and target customer profile of small-to-mid pharma.

TypeDirect peer
Description

Emergent operates contract sterile injectable manufacturing through its CDMO business along with proprietary products. A relevant peer for U.S.-based sterile fill-finish services targeting vaccine and injectable biologics.

TypeBroad incumbent
Description

Samsung Biologics is a large-scale biologics CDMO expanding into sterile fill-finish services. Represents an emerging large competitor in the biologics injectable space where August Bio is also investing.

TypeBroad incumbent
Description

Curia is a CDMO providing sterile injectable development and manufacturing services as part of a broader contract services portfolio. A comparable mid-to-large scale peer across multiple sterile injectable programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

August Bioservices

Sterile Injectable CDMO Servicesaugustbio.com

August Bioservices is a U.S.-based, Nashville-headquartered CDMO providing fully integrated development, analytical, and cGMP manufacturing services exclusively for sterile injectable drug products, serving pharmaceutical and biotech sponsors from clinical through commercial scale.

What August Bioservices does

August Bioservices, LLC is a U.S.-based contract development and manufacturing organization (CDMO) headquartered in Nashville, Tennessee, specializing exclusively in sterile injectable drug products. Founded in 2020 through the rebranding of PMI BioPharma and led by CEO Jenn Adams, the company operates an integrated three-service model spanning product development (formulation, process development, technology transfer, and scale-up), analytical services (full USP <1> release testing, stability, elemental impurities, extractables and leachables, nitrosamines, container closure integrity), and cGMP manufacturing (1L–4000L formulation scale across seven filling lines for vials, syringes, and IV bags, plus large-scale lyophilization and automated end-of-line inspection, packaging, and serialization). The facility is compliant with FDA Sterile Injectable Guidance, EU GMP Annex 1, and an ICH-based Quality Management System, enabling service to both U.S. and European pharmaceutical and biotech sponsors.

The business model is professional-services-based: revenue is generated through negotiated, project-based CDMO contracts with pharmaceutical and biotech clients, spanning modalities that include small molecules, peptides, enzymes, biologics, controlled substances, and lipid nanoparticles. Go-to-market is enterprise field sales with dedicated CDMO Business Development leadership, supported by attendance at major industry events (DCAT, CPHI, BIO, Contract Pharma, CDMO Live) and thought-leadership content in trade publications. The company has cumulatively raised approximately $88.6 million of institutional capital — including a $23.6 million Series A extension led by Polaris Partners (May 2021) and a $65 million Series B led by Oak HC/FT (December 2022) — alongside state grants, to fund a $64.7 million campus expansion that includes a 60,000 sq ft state-of-the-art commercial manufacturing facility, 180 planned new jobs over five years, and a 2025 strategic partnership with Optima for advanced fill-finish systems.

August Bioservices firmographics

Firmographics
Name
August Bioservices
Legal name
August Bioservices, LLC
Website
https://augustbio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
101–250 employees
Short description
August Bioservices is a U.S.-based, Nashville-headquartered CDMO providing fully integrated development, analytical, and cGMP manufacturing services exclusively for sterile injectable drug products, serving pharmaceutical and biotech sponsors from clinical through commercial scale.
Ownership category
akta.pro rank

August Bioservices industry classification

Industry
Product category
Sterile Injectable CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Sterile injectable CDMO
  • Pharmaceutical contract manufacturing
  • Aseptic fill-finish services
  • Biologics manufacturing services
  • Analytical testing services

Where August Bioservices is headquartered

Location

Headquarters

HQ city
Nashville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

August Bioservices business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Infrastructure, Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services: August Bioservices generates revenue through contract development and manufacturing organization (CDMO) services for pharmaceutical and biotech companies. Services span the full product lifecycle from early formulation development through commercial-scale manufacturing of sterile injectable drug products. Revenue is project-based with long-term contract relationships typical in the CDMO industry.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

August Bioservices product offering

Product offering

Core offering

August Bioservices is a U.S.-based Contract Development and Manufacturing Organization (CDMO) providing fully integrated drug development, analytical testing, and cGMP manufacturing services focused exclusively on sterile injectable drug products. The company serves pharmaceutical and biotechnology clients across formulation development, process development and technology transfer, comprehensive analytical and microbiological testing, and sterile fill-finish manufacturing for vials, syringes, and IV bags at scales from 1L to 4000L.

Product overview

August Bioservices is a US-based Contract Development and Manufacturing Organization (CDMO) providing fully integrated drug development, testing, and manufacturing services focused on sterile injectables. The company operates three interconnected service lines: Product Development Services (formulation, process development, technology transfer), Analytical Services (chemistry, microbiology, and characterization testing), and Manufacturing Services (sterile filling, inspection, packaging). Together these services span from early-stage lab-scale development through commercial-scale manufacturing for pharmaceutical and biotech clients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Product Development Services Scientific product development services for sterile injectables, including formulation development (liquid, homogenization, microfluidization, rotary evaporation, lab-scale lyophilization), process development and optimization, DoE and QbD study design and statistical analysis, and technology transfer and scale-up. Serves pharmaceutical and biotech clients developing modalities such as small molecules, peptides, enzymes, biologics, controlled substances, and lipid nanoparticles.
  • Analytical Services On-site Chemistry, Microbiology, Raw Material, and Analytical Development laboratories performing full USP <1> release testing for injectables, stability testing across all ICH Zones, elemental impurity testing (ICPMS), residual solvent testing (GCMS), extractables and leachables, nitrosamines, photostability, thermal cycling, and container closure integrity testing. Supports CMC submission readiness for pharmaceutical and biotech clients.
  • Manufacturing Services cGMP sterile injectable manufacturing services covering formulation at 1L to 4000L scale using stainless steel and single-use technology, sterile filling for vials, syringes, and IV bags (including drug-device combination products), lyophilization, and automated visual inspection, assembly, labeling, packaging, and serialization. Serves pharmaceutical and biotech clients from clinical through commercial supply.

Companies that use August Bioservices

Customer profile

Segments2 records

Ideal customer profiles2 records

August Bioservices technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

August Bioservices partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • OptimastrategicTechnology or Integration · 1 January 2025August Bio partners with Optima to enhance fill-finish flexibility with advanced systems for vials, pre-filled syringes, and cartridges. The partnership provides state-of-the-art equipment including Optima isolated high-speed vial filler and syringe filler systems. Optima's Turnkey approach and flexibility of solutions created real added value for August Bio's manufacturing operations.

Scale indicators6 records

Recent moves12 records

Expansion highlights6 records

August Bioservices competitors and assessment

Company assessment

Broad incumbents

  • Catalent: Catalent is one of the largest global CDMOs with deep sterile injectable fill-finish capabilities across vials, syringes, and prefilled devices. It competes head-to-head with August Bio for clinical and commercial sterile injectable programs but operates a much broader global network and larger customer book.
  • Lonza: Lonza is a global CDMO leader spanning small molecules, biologics, and cell/gene therapy, including sterile injectable drug product manufacturing. It is a relevant incumbent peer given August Bio's stated biologics and complex formulation capabilities.
  • Thermo Fisher Scientific (Patheon): Thermo Fisher's Pharma Services segment (including Patheon) offers large-scale sterile injectable development and manufacturing alongside oral solid dose and API services. A broader incumbent that competes with August Bio for commercial-scale sterile programs.
  • Recipharm: Recipharm is a European-headquartered CDMO with sterile injectable manufacturing capabilities alongside other dosage forms. A relevant incumbent competitor for cross-regional pharma sponsors.
  • Piramal Pharma Solutions: Piramal operates a global sterile injectable CDMO network (including its Lexington facility acquired from Coldstream). Comparable in modality coverage and customer segment to August Bio, though at larger scale.
  • Samsung Biologics: Samsung Biologics is a large-scale biologics CDMO expanding into sterile fill-finish services. Represents an emerging large competitor in the biologics injectable space where August Bio is also investing.
  • Curia (formerly AMRI): Curia is a CDMO providing sterile injectable development and manufacturing services as part of a broader contract services portfolio. A comparable mid-to-large scale peer across multiple sterile injectable programs.

Direct peers

  • Grand River Aseptic Manufacturing: Grand River is a U.S.-based CDMO focused on sterile injectable fill-finish for vials, syringes, and lyophilized products. Closely comparable to August Bio in scale, scope, and customer base of small-to-mid pharma and biotech sponsors.
  • Alcami: Alcami is a U.S.-based CDMO offering sterile injectable development, manufacturing, and analytical services. Directly comparable to August Bio in services offered and target customer profile of small-to-mid pharma.
  • Emergent BioSolutions: Emergent operates contract sterile injectable manufacturing through its CDMO business along with proprietary products. A relevant peer for U.S.-based sterile fill-finish services targeting vaccine and injectable biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

August Bioservices social profiles

Digital presence

August Bioservices compliance and trust

Trust signal

Compliance3 records

August Bioservices financial estimates

Financial estimate

Revenue estimate

Valuation estimate

August Bioservices leadership team

Management profile

Number of profiles

Profiles13 records

August Bioservices funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

August Bioservices M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about August Bioservices

What does August Bioservices do?

August Bioservices is a U.S.-based Contract Development and Manufacturing Organization (CDMO) providing fully integrated drug development, analytical testing, and cGMP manufacturing services focused exclusively on sterile injectable drug products. The company serves pharmaceutical and biotechnology clients across formulation development, process development and technology transfer, comprehensive analytical and microbiological testing, and sterile fill-finish manufacturing for vials, syringes, and IV bags at scales from 1L to 4000L.

Is August Bioservices a public or private company?

August Bioservices is a private company. It is classified as venture growth investor backed and is currently operating.

When was August Bioservices founded?

August Bioservices was founded in 2020. It employs 101 to 250 people.

Where is August Bioservices based?

August Bioservices is headquartered in Nashville, United States, in the North America region.

How does August Bioservices make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are August Bioservices's main competitors?

Broad incumbents on record are Catalent, Lonza, Thermo Fisher Scientific (Patheon), Recipharm, Piramal Pharma Solutions, Samsung Biologics and Curia (formerly AMRI). Direct peers are Grand River Aseptic Manufacturing, Alcami and Emergent BioSolutions.

Does August Bioservices have an API?

No public API is recorded for August Bioservices.

What industry is August Bioservices in?

August Bioservices's product category is Sterile Injectable CDMO Services. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Healthcare Technology Report.Jenn Adams named Healthcare Technology CEO of the YearJenn Adams, CEO of August Bioservices, was named Healthcare Technology CEO of the Year at the NYC Awards Night. She has led August Bioservices, a contract development and manufacturing organization focused on sterile injectable therapies, since its founding in 2020. The company aims to effectively partner with clients to advance innovative therapies from early development through commercialization.The Healthcare Technology Report.Jenn Adams Has a Track Record for Getting Healthcare BuiltJenn Adams, as CEO of August Bioservices, is shaping the company into a reliable partner for pharmaceutical and biotech firms with expertise in sterile injectable development and manufacturing. Since her appointment in 2020, she has overseen major renovations and expansions at August, underpinning her extensive 30-year career in healthcare leadership. Adams was recently recognized as Healthcare Technology CEO of the Year for her contributions to the industry.LivabilityHow Nashville, TN, is Shaping the Future of HealthcareNashville's healthcare ecosystem, anchored by over 900 companies, contributes nearly $68 billion locally and $97 billion globally. The Nashville Health Care Council promotes innovation through events and partnerships, while companies like August Bioservices and Hashed Health report rapid growth and expansion plans.TnecdPioneering the Future of Biotech in TennesseeAugust Bioservices, a Nashville-based CDMO, invested over $150 million and created more than 200 jobs after its November 2020 expansion announcement. It further invested $65 million in November 2022 to add 90 jobs and build new manufacturing lines. The company aims to become a magnet for other biotech firms in Middle Tennessee.Contractpharma"3 Key Trends" with Jason HartmanJason Hartman of August Bioservices discusses three CDMO trends: demand for lipid nanoparticle formulation, scale-up challenges for smaller firms, and the need for scalable capacity. August Bio's recent facility renovation added filling lines and clean rooms, positioning it to serve clients at every scale in 2023 and beyond.FinSMEsAugust Bioservices Closes $65M Series B FundingAugust Bioservices, a Nashville-based CDMO, raised $65M in Series B funding led by Oak HC/FT with Polaris Partners. The company will use the funds to add a sterile injectable filling suite and automate downstream processes to increase large-batch production capacity.Silicon Valley JournalsAugust Bioservices Raises $65M Series BAugust Bioservices, a pharmaceutical contract development and manufacturing organization, secured $65 million in Series B funding led by Oak HC/FT with participation from Polaris Partners. The company plans to utilize the capital to expand its sterile injectable filling capacity and automate downstream inspection processes to meet growing customer demand for U.S.-based manufacturing.AugustbioAugust Bioservices Closes $65M Series BAugust Bioservices secured $65 million in Series B funding led by Oak HC/FT with participation from Polaris Partners. The company plans to use the capital to expand its sterile injectable filling capacity and automate downstream processes at its Nashville facility.VC News DailyAugust Bioservices Announces $65M Series BAugust Bioservices announced that it secured $65 million in Series B funding, with Oak HC/FT leading the round. The funding aims to support the organization's role in accelerating drug development for biopharmaceutical and biotech companies. August Bioservices is a key player in the pharmaceutical contract development and manufacturing sector.BioSpaceAugust Bioservices Closes $65M Series BAugust Bioservices has closed a $65 million Series B funding round led by Oak HC/FT with participation from Polaris Partners. The capital will be used to expand sterile injectable manufacturing capacity at its Nashville facility, including adding a new filling suite and automating downstream processes. This expansion aims to meet growing demand for U.S.-based pharmaceutical manufacturing services.